Covalent Cysteine Targeting of Bruton’s Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells

Covalent Cysteine Targeting of Bruton’s Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells

Multiple myeloma (MM) is a hematological malignancy characterized by plasma cells’ uncontrolled growth. The major barrier in treating MM is the occurrence of primary and acquired therapy resistance to anticancer drugs<b>. </b>Often, this therapy resistance is associated with constitutive...

Full description

Bibliographic Details
Main Authors: Emilie Logie, Chandra S. Chirumamilla, Claudina Perez-Novo, Priyanka Shaw, Ken Declerck, Ajay Palagani, Savithri Rangarajan, Bart Cuypers, Nicolas De Neuter, Fazil Mobashar Hussain Urf Turabe, Navin Kumar Verma, Annemie Bogaerts, Kris Laukens, Fritz Offner, Pieter Van Vlierberghe, Xaveer Van Ostade, Wim Vanden Berghe
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
withaferin A
BTK
multiple myeloma
therapy resistance
glucocorticoids
ibrutinib
Online Access:https://www.mdpi.com/2072-6694/13/7/1618

Internet

https://www.mdpi.com/2072-6694/13/7/1618

Similar Items